A Phase 4, Open-Label Study to Evaluate the Efficacy of Valbenazine on Clinician- and Patient-Reported Outcomes in Patients With Tardive Dyskinesia (TD) Who Remain Symptomatic While on Deutetrabenazine or After Discontinuing Prior TD Treatment With a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.

Start Date29 Aug 2025

Sponsor / Collaborator

Neurocrine Biosciences, Inc.

NCT06107829

/ WithdrawnPhase 4IIT

Identification, Assessment, and Treatment of Tardive Dyskinesia With Valbenazine in Adults With Intellectual/Developmental Disabilities and Co-occurring Psychiatric and/or Behavioral Disorders

The goal of this open-label clinical trial is to test the safety and efficacy of valbenazine treatment in patients with Intellectual/Developmental Disability (IDD) who have a diagnosis of Tardive dyskinesia (TD). The main questions this study aims to answer are:
* Does valbenazine treatment of TD in the previously untreated patient population of adults with IDD produce comparable amelioration of signs of movement disorder as what has historically been reported in adults without IDD?
* Is valbenazine treatment of TD in persons with IDD as safe as what has historically been reported in adults without IDD?
* Does valbenazine treatment improve Quality of Life (QOL) in persons with IDD and TD treated with valbenazine?
* Does valbenazine treatment produce positive change in Activities of Daily Living (ADLs) in persons with IDD and TD?
* Does valbenazine treatment of TD in persons with IDD reduce caregiver burden?
In this study, 25 participants with IDD and TD will undergo valbenazine treatment for 24 weeks. The participants will be seen for a total of 5 visits: at baseline, and at follow up visits at 3 weeks, 6 weeks, 12 weeks, and 24 weeks.
This study does not include a comparison group. Therefore, researchers will compare the response of the study participants to valbenazine treatment with those from a previous reported work that resulted in the FDA approval of this medication.

Start Date01 Jan 2025

Sponsor / Collaborator

University Hospitals Cleveland Medical Center

[+1]

NCT06771323

/ RecruitingPhase 2IIT

Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia

The most common form of idiopathic dystonia is adult-onset cervical dystonia (CD), a focal form of dystonia affecting the muscles of the neck. CD is often associated with pain and limited range of motion, and frequently leads to reduced quality of life and disability. Effective long-term treatment options are extremely limited. Recurring botulinum neurotoxin (BoNT) injections can ease the symptoms of CD, but they frequently provide only partial relief and can be associated with intolerable side effects. Deep brain stimulation can be used to treat more severe cases of CD, but this neurosurgical procedure is invasive, on average only about 50% effective and may lead to serious adverse effects. Novel treatment approaches for CD are desperately needed to alleviate symptoms and improve the quality of life for the many who suffer from this chronic and disabling neurological disorder.

Start Date17 Dec 2024

Sponsor / Collaborator

Virginia Commonwealth University

100 Clinical Results associated with Valbenazine Tosylate

100 Translational Medicine associated with Valbenazine Tosylate

100 Patents (Medical) associated with Valbenazine Tosylate

Literatures (Medical) associated with Valbenazine Tosylate

01 Apr 2026·JOURNAL OF PHARMACY PRACTICE

Lurasidone-Induced Tardive Dyskinesia Reversed With Lithium Therapy: A Case Report

Article

Author: Pinkhasov, Aaron ; Jacobsohn, Tamar ; Gelman, Alice ; Yi, Hyogun

Tardive dyskinesia (TD) is a syndrome that causes chronic, involuntary, and disruptive movements of the body and/or face that is a severe, potentially irreversible adverse effect of long-term antipsychotic use. It has wide-reaching effects on patients’ well-being, quality of life, 1 and treatment adherence. 2 Thus, TD is debilitating, leading to social withdrawal, 3 and workplace absenteeism. 1 Current data on tardive dyskinesia treatment are limited, and prevention, primarily through the modification of antipsychotic regimens, remains the most effective strategy. 4 Recent systematic review has shown valbenazine and vitamin E are the only treatments significantly more effective compared to placebo in treatment of TD, although valbenazine is associated with significant side effects. 5 We present a case of a 76-year-old female with a diagnosis of Bipolar II Disorder (BD) who developed TD after treatment with lurasidone for 10 years. After struggling with both her BD and TD symptoms for 3 years, she sought care at our clinic where we prescribed 300 mg daily of lithium. At her follow-up visit 5 weeks later, her TD symptoms were greatly improved, with sustained benefits observed at following visits. This article reviews the literature discussing the interplay between lithium and TD and presents a case report of TD improvement after lithium augmentation for treatment-resistant depression. While this case suggests a potential role in TD treatment, the role of lithium in TD treatment remains controversial.

01 Mar 2026·JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

The Use of VMAT2 Inhibitors for Tardive Dyskinesia

Article

Author: Stroup, T. Scott ; Gerhard, Tobias ; Olfson, Mark ; Alabaku, Orges

Background::

Vesicular monoamine transporter 2 inhibitors (VMAT2-Is), valbenazine and deutetrabenazine, are the only FDA-approved medications for tardive dyskinesia (TD); tetrabenazine is used off-label. TD diagnosis and VMAT2-I use data remain limited. This study characterizes trends in TD diagnosis and VMAT2-I use among adults (aged 18 to 65 years) with mental health diagnoses receiving antipsychotics.

Methods::

We analyzed 2017-2022 MarketScan data. TD and mental health diagnoses were identified using ICD-10 codes, and VMAT2-I use from prescription claims. Mental health diagnoses were hierarchically categorized as schizophrenia, bipolar disorder (BPD), major depressive disorder (MDD), or other. Descriptive analyses summarized trends, and multivariable logistic regression assessed predictors of VMAT2-I use.

Results::

Among a cohort of 729,262 adults, TD diagnosis increased from 0.45% (N=849) in 2017 to 0.57% (N=1194) in 2022. VMAT2-I use increased from 0.05% (N=100) to 0.22% (N=454). Predictors of VMAT2-I use included first-generation antipsychotic use versus second-generation use only [adjusted odds ratio (aOR): 2.06, 95% CI: 1.59-2.67], schizophrenia (aOR: 8.40, 95% CI: 6.57-10.74) or BPD (aOR: 3.18, 95% CI: 2.62-3.86), versus other mental health diagnoses, female versus male sex (aOR: 1.32, 95% CI: 1.14-1.51), age 51 to 65 versus age 18 to 34 years (aOR: 5.57, 95% CI: 4.63-6.71), and calendar year (aOR: 1.42 95% CI: 1.36-1.48). Among patients with TD, schizophrenia (aOR: 1.80; 95% CI: 1.26-2.57), BPD (aOR: 1.85; 95% CI: 1.39-2.46), and age [aOR: 3.55; 95% CI: 2.70-3.84 (51 to 65 vs. 18 to 34 y)] were predictors of VMAT2-I use.

Conclusions::

TD remains underdiagnosed, with treatment rates low, highlighting the need for improved TD recognition and VMAT2-I access.

01 Dec 2025·JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetic and Exposure‐Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea Management

Article

Author: Chapel, Sunny ; Loewen, Gordon ; Brar, Satjit ; Nguyen, Hoa Q. ; Kuan, Han‐Yi Steve ; Crass, Ryan L.

Abstract:

Valbenazine improved chorea in individuals with Huntington's disease compared to placebo in a phase 3, placebo‐controlled study (KINECT‐HD). Population pharmacokinetics (PK) and exposure–response (E–R) analyses focused on understanding the PK characteristics of valbenazine and its active metabolite, [+]‐α‐dihydrotetrabenazine ([+]‐α‐HTBZ), and their correlation with clinical efficacy measured by the total maximal chorea (TMC) score. Consistent with previous analyses, a two‐compartmental population PK model adequately described valbenazine and [+]‐α‐HTBZ plasma disposition, generating reliable individual‐predicted exposure levels for sequential E–R analysis. The distributions of individual‐predicted steady‐state exposures of valbenazine and [+]‐α‐HTBZ were found to largely overlap between patients with tardive dyskinesia and those with Huntington's disease (HD) chorea. The relationship between the change from baseline in TMC score and [+]‐α‐HTBZ systemic exposure were effectively characterized by a nonlinear E max model, with negligible impact from selected covariates. The predicted E–R curve closely aligns with the observed data, exhibiting a negative slope that indicates an increasing clinical response with escalating doses of 40, 60, and 80 mg/day. Predicted efficacy appears to reach a plateau at 80 mg once daily (QD), suggesting minimal additional benefit beyond this dosage. Together, results from the population PK model and E–R analyses reinforce the evidence base for valbenazine efficacy in reducing chorea severity, as demonstrated by the notable decrease in TMC scores compared to baseline. They also endorse the selection of dosing regimens ranging from 40 to 80 mg QD for the treatment of chorea in patients with HD.

217

News (Medical) associated with Valbenazine Tosylate

26 Mar 2026

·neurocrine.gcs-web.com

Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings

Expert panel establishes structured approach to tardive dyskinesia screening, diagnosis and treatment in long-term care, including use of VMAT2 inhibitors New post-hoc KINECT‑PRO™ analysis in adults aged 65 years and older demonstrates clinically meaningful patient-reported improvements in tardive dyskinesia impact with INGREZZA® (valbenazine) capsules, reinforcing expert panel recommendations SAN DIEGO, March 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among older adults in long-term care settings. Developed through a multidisciplinary Delphi panel, the recommendations address persistent gaps in recognizing and managing tardive dyskinesia in this higher-risk population. Findings were presented at the Society for Post-Acute and Long-Term Care Medical Association (PALTmed) PALTC26 Annual Conference in Anaheim, Calif. The company also presented a first-of-its-kind post-hoc analysis from the KINECT‑PRO™ study demonstrating meaningful improvements in patient‑reported tardive dyskinesia (TD) impact among adults aged 65 years and older treated with INGREZZA® (valbenazine) capsules. This analysis adds to the growing body of evidence supporting the appropriateness, efficacy, tolerability and established safety profile of INGREZZA in this patient population. "To date, there has been limited practical guidance tailored specifically to the screening, diagnosis and treatment of tardive dyskinesia in the long-term care setting," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "The consensus recommendations provide structured guidance for clinicians caring for residents in these environments, and the KINECT-PRO findings demonstrate clinically meaningful patient-reported improvements in the impact of tardive dyskinesia with INGREZZA in adults aged 65 years and older. Together, this guidance and evidence help support more informed treatment decisions in this population that may be at higher risk for tardive dyskinesia." Older adults in long-term care are at an elevated risk for TD due to prolonged exposure to dopamine receptor blocking agents, advanced age, polypharmacy and complex comorbidities. Recognition and management may be further complicated in residents who are non-ambulatory, cognitively impaired or unable to reliably report symptoms. The Delphi panel was convened to develop recommendations that reflect this clinical complexity and support a more consistent, structured approach to TD care. "Residents in long-term care settings often present with overlapping medical and psychiatric complexities that can make tardive dyskinesia difficult to consistently recognize and manage," said Amita Patel, M.D., the poster's lead author and psychiatrist at the Joint Township District Memorial Hospital in St. Mary's, Ohio. "Through this process, the panel reached clear consensus on practical, implementable recommendations that support evidence-based diagnosis and appropriate use of VMAT2 inhibitors. These recommendations provide clinicians with a structured framework to guide screening and treatment decisions to help improve outcomes for this especially vulnerable population." Screening and Diagnosing TD in Long-Term Care Settings Requires a Holistic Approach The panel identified key considerations to support routine and consistent TD screening in long-term care settings. These include: Use of the Abnormal Involuntary Movement Scale (AIMS) for screening and assessing TD. Quarterly screening for residents treated with dopamine receptor blocking agents, the primary cause of TD. Regular assessment of the impact of TD on residents' well-being, including feedback from residents, family members, caregivers and the broader care team. Treatment Selection Should Consider Relevant Patient Factors Panelists also reached consensus that TD should be treated with a vesicular monoamine transporter 2 (VMAT2) inhibitor in long-term care settings and identified several treatment-selection factors particularly relevant in these environments. These include: Formulation flexibility for residents who experience dysphagia or difficulty swallowing. Simplified administration, including the availability of a therapeutic starting dose. Consideration of polypharmacy and potential drug-drug interactions. Availability of clinical data in adults aged 65 years and older. These considerations underscore the importance of selecting a therapy with a clinical profile and administration characteristics that align with the needs of long-term care residents. INGREZZA is approved for the treatment of adults with TD and, among approved VMAT2 inhibitors: has been studied extensively in adults aged 65 years and older. is the only VMAT2 inhibitor without a cautious dosing recommendation in this population. is the only treatment that offers a therapeutic dose from day one with no required titration. is available in a sprinkle formulation. has a safety profile in adults aged 65 years and older that is consistent with that observed in patients younger than 65 years of age.* Phase 4 KINECT-PRO Findings Reinforce Significance of Expert Consensus Guidelines A post-hoc analysis of the KINECT-PRO study complements the consensus recommendations by demonstrating the real-world impact of INGREZZA treatment in older adults. KINECT-PRO is the first and only clinical study to specifically evaluate and investigate patient-reported improvement with INGREZZA for TD using multiple validated scales, including the Tardive Dyskinesia Impact Scale (TDIS™). In adults aged 65 and older, once-daily INGREZZA was associated with robust patient-reported improvements in TD symptoms, quality of life and functional impairment at Week 24. Patient-reported outcomes also demonstrated reduced social and emotional burden, with improvements in total TDIS scores exceeding the established threshold for clinically meaningful change. Additional presentations at the Society for Post-Acute and Long-Term Care Medical Association (PALTmed) PALTC26 Annual Conference include: Management of Tardive Dyskinesia in Long-Term Care: Application of the 4Ms Framework Physical, Mental, and Socioemotional Functional Improvement Following Valbenazine Treatment in Patients with TD Residing in Long-term Care Settings Valbenazine Treatment for Tardive Dyskinesia in a 64-Year-Old Female Presenting with Nonhealing Wounds due to Truncal Dyskinesias: A Case Report * Safety profiles as demonstrated in a post-hoc analysis from two 48-week studies (KINECT® 3 extension and KINECT® 4). About Tardive Dyskinesia Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrolled, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (antipsychotics) that help control dopamine receptors in the brain. Taking antipsychotics commonly prescribed to treat mental illnesses such as major depressive disorder, bipolar disorder, schizophrenia and schizoaffective disorder and other prescription medicines (metoclopramide and prochlorperazine) used to treat gastrointestinal disorders are associated with TD. In patients with TD, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of TD can be mild to severe and are often persistent and irreversible. TD is estimated to affect at least 800,000 adults in the U.S. About the KINECT-PRO™ Phase 4 Study The KINECT-PRO™ Phase 4, open-label study was designed to evaluate patient-reported outcomes on the use of INGREZZA® (valbenazine) capsules in a tardive dyskinesia (TD) patient population reflective of real-world clinical practice. Participants had at least mild TD, were aware of and experiencing at least mild distress from their abnormal, involuntary movements and had a clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or major depression. The KINECT-PRO study included a four-week screening period, a 24-week treatment period during which participants received 40 mg of INGREZZA once-daily for the first four weeks, followed by flexible dosing of 40 mg, 60 mg or 80 mg once-daily based on individual treatment needs and a two-week safety follow-up period. Baseline socio-demographic and clinical characteristics of the participants were broadly similar to those of the KINECT® 3 and KINECT® 4 studies. KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on TD using multiple clinically validated scales, including the Tardive Dyskinesia Impact Scale (TDIS™). The TDIS is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. About the Tardive Dyskinesia Impact Scale The Tardive Dyskinesia Impact Scale (TDIS™) is the only patient-reported outcome instrument designed for and validated in tardive dyskinesia patients that measures the physical, social and emotional impact of the involuntary movements of the condition. It was developed by Neurocrine Biosciences from qualitative studies and Phase 3 trials of INGREZZA for the treatment of TD (KINECT® 3 and KINECT® 4) as a comprehensive measure of impact and burden of TD from a patient's perspective. The TDIS consists of 11 questions evaluating physical and socio-emotional impact. Six scales are assessed: mouth/throat, dexterity, mobility, pain, social and emotional. The TDIS allows people with TD to rate how their symptoms affect daily activities and how their uncontrollable movements make them feel. The questionnaire captures relevant information about the impact of TD to provide a more holistic assessment of the condition. Validation of this scale was published in the Journal of Patient-Reported Outcomes. About INGREZZA® (valbenazine) Capsules and INGREZZA® SPRINKLE (valbenazine) Capsules INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration. INGREZZA, developed by Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements. INGREZZA is studied across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules. Important Information Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia). involuntary movements (chorea) of Huntington's disease. INGREZZA or INGREZZA SPRINKLE do not cure the cause of involuntary movements, and do not treat other symptoms of Huntington's disease, such as problems with thinking or emotions. It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children. IMPORTANT SAFETY INFORMATION INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself. Do not take INGREZZA or INGREZZA SPRINKLE if you: are allergic to valbenazine, or any of the ingredients in INGREZZA or INGREZZA SPRINKLE. INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including: Allergic reactions. Allergic reactions, including an allergic reaction that causes sudden swelling called angioedema, can happen after taking the first dose or after many doses of INGREZZA or INGREZZA SPRINKLE. Signs and symptoms of allergic reactions and angioedema include: trouble breathing or shortness of breath, swelling of your face, lips, eyelids, tongue, or throat, or other areas of your skin, trouble with swallowing, or rash, including raised, itchy red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Stop taking INGREZZA or INGREZZA SPRINKLE and go to the nearest emergency room right away if you develop these signs and symptoms of allergic reactions and angioedema. Sleepiness and tiredness that could cause slow reaction times (somnolence and sedation). Do not drive a car or operate dangerous machinery until you know how INGREZZA or INGREZZA SPRINKLE affects you. Drinking alcohol and taking other medicines may also cause sleepiness during treatment with INGREZZA or INGREZZA SPRINKLE. Heart rhythm problems (QT prolongation). INGREZZA or INGREZZA SPRINKLE may cause a heart rhythm problem known as QT prolongation. You have a higher chance of getting QT prolongation if you also take certain other medicines during treatment with INGREZZA or INGREZZA SPRINKLE. Tell your healthcare provider right away if you develop any signs or symptoms of QT prolongation, including: fast, slow, or irregular heartbeat (heart palpitations), shortness of breath, dizziness or lightheadedness, or fainting or feeling like you are going to faint. Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, irregular pulse or blood pressure, increased sweating, or very fast or uneven heartbeat. Parkinson-like symptoms. Symptoms include: body stiffness, drooling, trouble moving or walking, trouble keeping your balance, shaking (tremors), or falls. Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days. The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia are sleepiness and tiredness. The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep. These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. Dosage Forms and Strengths: INGREZZA and INGREZZA SPRINKLE are available in 40 mg, 60 mg, and 80 mg capsules. Please see full Prescribing Information, including Boxed Warning, and Medication Guide. About Neurocrine Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie) The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, KINECT and INGREZZA are registered trademarks of Neurocrine Biosciences, Inc. KINECT-PRO and TDIS are trademarks of Neurocrine Biosciences, Inc. Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA, the interpretation and potential relevance of the data described in this press release, including statements regarding the use and interpretation of the Tardive Dyskinesia Impact Scale (TDIS™), and the value INGREZZA may bring to patients. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of INGREZZA; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA; whether INGREZZA receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2025. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law. © 2026 Neurocrine Biosciences, Inc. All Rights Reserved. CAP-VBZ-US-0094 03/2026 View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-first-expert-consensus-recommendations-for-tardive-dyskinesia-in-long-term-care-settings-302725473.html SOURCE Neurocrine Biosciences, Inc. Neurocrine Biosciences, Inc.  Media: Aimee White, 1-858-354-7865, media@neurocrine.com; Investors: Todd Tushla,1-858-617-7143, ir@neurocrine.com

Phase 3Clinical ResultDrug Approval

20 Mar 2026

·endpoints.news

Idorsia looks for another CEO — again; Former Jazz exec makes a comeback

→ Srishti Gupta took over as CEO of Idorsia last summer, but the job is open again as chairman Jean-Paul Clozel kicks off another search. Idorsia’s shares dropped more than 13% on the Swiss exchange when the news broke on Monday. Gupta was called up from the board of directors to replace André Muller , who retired in July 2025 after just a year in the top spot. During Muller’s brief tenure, Idorsia came up empty on a proposed licensing deal for Tryvio , but the FDA gave the green light for its updated label , saying the blood pressure medicine didn’t need a REMS requirement. → George Eliades hopes to once again give a bounce to Jazz Pharmaceuticals , the oncology and neuro drugmaker that he left in 2024. Eliades is returning to the Irish and US biopharma under his previous title of chief transformation officer. He played a different tune for the past two years, serving as CEO of Mythic Therapeutics , but that bet fizzled out due to lackluster interest from investors in the clinical-stage ADC startup. Now he’s returning to a revamped Jazz to “help accelerate our next phase — sharpening our focus, strengthening execution, and ensuring we’re positioned to deliver meaningful impact for patients and their families,” according to a LinkedIn post. Since his departure in the spring of 2024, Jazz welcomed a new CEO, acquired Chimerix for a now- approved brain tumor treatment, inked the highest priority review voucher sale in a decade, and continued to expand its epilepsy pipeline . → Andy Nixon wrote about his departure from Boehringer Ingelheim on LinkedIn and posted a photo holding a cool going-away present: a Gibson guitar. Nixon spent the last five years as global head of biotherapeutics discovery research at the German pharma giant and had a 17-year career with Dyax . “The unexpected gift of the guitar perfectly highlighted what I’ve always valued during my time at Boehringer: being seen and appreciated as a complete person,” Nixon said, adding, “The genuine appreciation shown at my recent farewell event made leaving a much harder step than I anticipated.” → Purple Biotech ’s Gil Efron will step aside in August after four years as CEO and eight years overall. Efron was elevated to president and CFO in July 2021 and succeeded Isaac Israel as CEO a year later. The Israeli cancer biotech’s lead asset is a trispecific antibody for solid tumors called CAPTN-3 . Efron will stay on the board of directors. → Amphista Therapeutics CSO Louise Modis will now be taking over the company from retiring CEO Antony Mattessich , marking another female chief exec in the biotech circle. Modis joined the UK molecular glue biotech in 2023 after a gig as CSO at Mogrify . Before that, she had a seven-year stint at GSK and an eight-year run with Boehringer Ingelheim. Besides Modis’ appointment, Amphista also announced Patrick Kelly as CMO, having served in the same role at Forma Therapeutics , where he helped lead development of olutasidenib . → Korsana Biosciences , the latest startup out of biologics shop Paragon Therapeutics , has secured a CFO with IPO experience. Mark Vignola departed the CFO post at Terns Pharmaceuticals last winter, months before the drug developer ditched its obesity plans to go all in on cancer. Korsana doesn’t appear to be in immediate need of a finance whiz: The company raised a massive $150 million launch round in the fall of 2025, but waited until last month to unveil its Alzheimer’s ambitions that are eerily similar to Roche ’s late-stage program that penetrates the blood-brain barrier. → AbbVie ’s new head of M&A comes from GSK’s search and evaluation team. Garrett Rhyasen has jumped from the UK pharma giant, which is undergoing a CEO transition, to the Chicago-area drugmaker as VP of business development and acquisitions. Rhyasen is joining one of the most active BD teams in industry. AbbVie is digesting about 30 transactions worth $8 billion over the past two years, as noted by finance chief Scott Reents at Leerink ’s healthcare conference in Miami last week. → Harbour BioMed has named Jenny Xie as chief scientific officer for immunology and head of global external innovation for the Hong Kong-listed biotech with operations across China, Europe and the US. Xie was previously head of discovery immunology at Bristol Myers Squibb , where she spent the past 20 years and worked on “tolerance induction, immune reset and tissue repair,” with tools such as T cell engagers, according to her LinkedIn bio. Harbour has built a suite of partnerships in immunology, including with Xie’s longtime former employer and AstraZeneca . → Australian biotech Mesoblast has welcomed Teresa Montagut as its first head of clinical development and medical affairs. Montagut spent more than five years with Regeneron and had been global head of early pipeline studies in oncology, as well as head of medical affairs for investigator-sponsored studies of gastrointestinal and genitourinary conditions. Mesoblast wants to expand the label for its graft-versus-host disease treatment Ryoncil , the first-ever mesenchymal stromal cell therapy to receive an FDA approval . → We’ve got a few promotions to discuss, starting at Neurocrine . Andrew Ratz has been bumped up to chief technical operations officer after a year as SVP of drug development, delivery and device. He had an assortment of roles over 28 years at Eli Lilly , including SVP, delivery, device and connected solutions. Neurocrine’s Ingrezza is already approved for tardive dyskinesia and for chorea in patients with Huntington’s disease, but the San Diego biotech said in December that the drug flopped in a Phase 3 study for dyskinetic cerebral palsy. → Molecular glue specialist Monte Rosa Therapeutics said in its Q4 update that it has promoted its drug discovery leader Magnus Walter to chief technology officer, and Andrew Funderburk to chief investor relations and strategy officer. Walter is a longtime Lilly veteran who then worked for AbbVie as head of discovery chemistry, screening biology and operations. Funderburk joined Monte Rosa in 2024 as SVP, investor relations and strategic finance. Back in September, Novartis shelled out $120 million upfront for its second molecular glue deal with Monte Rosa in as many years. → Ajay Nirula has catapulted to president of Recludix Pharma and will continue to lead R&D, while the San Diego biotech has also promoted Catherine Bovenizer to CFO. Bovenizer held this position at Renova Therapeutics before she jumped to Recludix in 2020, and she had been SVP of finance and business operations since 2022. Peer Review told you about Nirula’s appointment as head of R&D in 2024, ending an eight-year run with Lilly. Recludix has been dosing healthy volunteers for a Phase 1 study of its Sanofi – partnered STAT6 inhibitor REX-8756 , good for a $20 million milestone payment. → IsomAb has a new CEO : Philip Brainin will now be steering the ship of the UK biotech, succeeding Jackie Turnbull . Brainin spent eight years on the medical side of things in Region Hovedstaden and previously was with Sound Bioventures , where he helped advise companies including Boost Pharma , VarmX and AnaCardio . Besides Brainin, IsomAb has also swapped out chairman Paul Edwards , who will remain on the board, with Anker Lundemose . → Cambridge, UK-based Alchemab Therapeutics has recruited Ulrich Wendt as CBO, ending a 25-year career with Sanofi in numerous capacities. He was global head of business development for the French pharma’s immunology & inflammation franchise for the past six years. Alchemab’s ALS candidate ATLX-1282 is at the heart of a licensing deal with Lilly that could be worth as much as $415 million. → Bispecific antibody developer Bambusa Therapeutics has welcomed Todd James as CFO. James was SVP, corporate affairs and investor relations at Viridian and from 2015-21 he was with Acceleron , where he helped secure more than $1 billion in financing. Bambusa was founded by BioNTech veterans Shanshan Xu and Helmut Jeggle and collected $140 million in Series A financing last year. The money will be used to fund clinical- and early-stage candidates, including dermatology and respiratory drugs BBT001 and BBT002 . → Early cancer detection company ClearNote Health has rolled out Jeffrey Venstrom as CMO. Ventstrom served in the same role at cancer screening company Grail , which last week announced that its CEO Bob Ragusa was retiring . Besides Ventstrom, ClearNote also hired Daniel Black as general manager of international markets, Jeremy Bennett as head of marketing, and promoted Irene Hsieh to VP of regulatory affairs and quality assurance. → Besides collecting $40 million this week, Mestag Therapeutics has also brought on Lindsey Rolfe as CMO and Pascal Merchiers as chief development officer. Rolfe served in the same role at both radiotherapy company 3B Pharmaceuticals and Clovis Oncology , where she helped secure marketing approvals in the US and Europe for Rubraca in ovarian and prostate cancer. Meanwhile, Merchiers has served in roles at Commit Biologics , Oncurious , Roche-acquired Tusk Therapeutics and Galapagos . The cash injection will help fund Mestag’s Phase 1 trial, slated to start in mid-2026, which will evaluate its candidate MST-0312 in cancer. → Virginia-based CDMO Phlow has plucked up Dawn Von Rohr as COO. Von Rohr joins the team after a stint as life sciences division president of Pace Life Sciences . Von Rohr had a long career at Mallinckrodt , ending a 22-year run with the company with her role as VP and general manager, global APIs. Last July, Phlow picked up $37 million in a Series C raise, looking to expand its API and key starting material manufacturing capacity in the US. → One of the industry’s longest-tenured investors, Frazier Life Sciences , has a fresh face in its biotech-building shop. Mansi Shinde is now VP of company creation at the firm. She was in corporate development roles at Nvelop Therapeutics and then carried on those duties when it merged with Chroma Medicine to become nChroma . Shinde helped form new biotech companies during a couple-year stint at 4:59 , the incubator unit of 5AM Ventures . She will be based in Frazier’s Boston office alongside colleagues Lauren Mifflin and Joe Cabral . The Frazier ecosystem is massive, with more than $5 billion in capital spread across both venture-backed startups and publicly traded life sciences companies. → Vertex Ventures has lost managing director Christine Brennan to another life sciences investor. Brennan departed the Temasek – backed firm to return to the corporate venture capital and large pharma strategy side of the industry. This week, she joined Johnson & Johnson Innovation , or JJDC , as a partner in the healthcare giant’s Cambridge office. As Brennan wrote in a LinkedIn post , she has “huge shoes to fill” in succeeding Marian Nakada , who left in September after more than a dozen years working on investing strategy at one of the oldest corporate venture arms in existence. Brennan has worked in CVCs before, having spent multiple years at Merck and Novartis’ units. → Royalty Pharma is in Peer Review for the second time this month as the royalty aggregator poaches a bulge bracket banker to help expand its portfolio. Greg Butz , Bank of America ’s global co-head of healthcare investment banking, will become EVP of partnering and investments at Royalty. The firm added a head of Asia this spring, plucking Kenneth Sun from Morgan Stanley . Meanwhile, Royalty said five-year company veteran Chris Hite is now its chair of partnering and investments. The Citi alum just picked up a board seat at Vera Therapeutics . → CSL Behring’s Korean subsidiary has recruited Se-eun Hwang as its new manager. Hwang was previously general manager of Biogen Korea and held roles at Abbott Korea and JW Pharmaceutical . Earlier this week, CSL announced that its hemophilia B gene therapy Hemgenix was temporarily out of stock , warning that some patients would experience delays in treatment. → Synthetic biology company Antheia has picked up Chris Savile as VP, business development and partnerships. Savile spent six years as CEO of Willow Biosciences , which sold its operating subsidiary in 2025 to become Evolutia Bio , while the rest of the company rebranded as Atlas Energy Corp and pivoted to international oil and gas royalty. Savile also previously held roles at Intrexon and Codexis . Antheia, which is partnered with Ginkgo Bioworks , hauled in $56 million in a Series C financing round last year to commercialize its API product thebaine , boost its US capacity and expand into Singapore. → Stockholm-based pediatric skeletal disease biotech Boost Pharma has enlisted Elaine Jones as chair of its board. Jones succeeds Ingelise Saunders , who will remain on the board. Jones’ résumé is stacked with board seats, including at CytomX , NextCure and Gritstone bio . Now led by former Galecto CEO Hans Schambye , Boost is developing a cell therapy for osteogenesis imperfecta, a rare bone disease with no approved treatments. → Radiopharma biotech Convergent Therapeutics has added former Y-mAbs CEO Michael Rossi to its board of directors. Rossi’s 30-year experience in radiopharmaceuticals through his previous roles — including Mirion Technologies , Advanced Accelerator Applications and Jubilant Radiopharma — will help the company and its radioantibody candidate CONV01-α , which is finishing up its Phase 2 trial in metastatic castration-resistant prostate cancer. → Muna Therapeutics CEO Rita Balice-Gordon has joined the board of directors at Lundbeck . Balice-Gordon started with Muna in 2020 as CSO before taking the top exec spot the next year. Under her leadership, Muna forged a pact with GSK in Alzheimer’s in 2024. Earlier this month, Lundbeck CEO Charl van Zyl told Endpoints News’ Zach Brennan that the company would not be forging a “most favored nation” deal with the White House, but instead would participate in one of the CMS pilots.

Executive ChangePhase 1Drug ApprovalPhase 2

12 Feb 2026

·www.biopharmadive.com

Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor

With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies results and how theyre being received by investors. Today, were offering insight into the latest numbers from Neurocrine Biosciences, Alnylam Pharmaceuticals and Ascendis Pharma. Neurocrine again disappoints some investorsShares of Neurocrine Biosciences fell by over 10% on Thursday, wiping more than $1 billion in value from the brain-focused biotechnology company.The drop followed a Wednesday afternoon earnings report in which Neurocrine said net product sales in the fourth quarter and 2025 overall totaled $798 million and $2.83 billion. Those figures are respectively 29% and 22% higher year-over-year. Ingrezza, a drug for movement issues associated with Huntington's disease, accounted for more than 80% of overall sales. The remainder mostly came from Crenessity, a treatment approved in 2024 for a rare, genetic condition that can cause life-threatening shortages of crucial hormones.Brian Abrahams, an analyst at RBC Capital Markets, suspects a combination of factors may be concerning some investors. One is Neurocrine's guidance. The company expects that, over the course of this year, net sales from Ingrezza will be in the range of $2.7 billion to $2.8 billion. That might not be as high as shareholders had hoped. Neurocrine executives also recently disclosed plans to spend another $150 million building out the sales teams for those two leading products a decision that could be seen as bad for near-term margins.Additionally, Abrahams noted how some are worried about Crenessitys growth prospects, specifically with regard to the number of new patients starting on the drug. Neurocrine says there are roughly 20,000 people in the U.S. with that rare condition, congenital adrenal hyperplasia, and, across last year, about 2,050 began taking Crenessity. Sales figures indicate the final three months of 2025 averaged fewer starts, at 431, than previous quarters.Even so, Abrahams and his team see the fears as overblown. Though we acknowledge investor consternation around margins and Crenessity launch dynamics could persist ... we believe todays downside reaction will prove to be a compelling buying opportunity, he wrote in a note to clients.Ingrezza looks poised for a major beat, he added, and Crenessity should be fine [as] we have always anticipated some continued slowdown in new patient starts.Overall, we see much growth left in both key franchises, wrote TD Cowen analyst Phil Nadeau in his own client note.Alnylam bitten by its successA similar situation played out with Alnylam Pharmaceuticals. The company, which specializes in so-called RNA interference drugs, gave a preliminary look at fourth-quarter and full-year earnings last month, then released its official report Thursday. It recorded nearly $3 billion across all of 2025 and almost $1 billion over those final three months, reflecting increases of 81% and 121% compared to the same periods the prior year.Despite that performance, Alnylam shares had slipped around 4% by the time trading closed Thursday afternoon.Though the company sells half a dozen drugs, nearly 80% of its product revenue comes from Amvuttra, a treatment for the nerve damage and heart failure associated with a rare disorder known as ATTR. Alnylam has said this disorder, which has a couple subtypes, affects north of a few hundred thousand people worldwide. For 2026, the company expects net product revenue to reach $4.9 billion to $5.3 billion, with Amvuttra and another ATTR medicine, Onpattro, responsible for up to $4.7 billion of that sum.To Paul Matteis, an analyst at Stifel, the main debate among investors is whether Amvuttra can meet or beat this guidance, and whether Alnylam can keep pace finding new patients to get on the drug.Alnylam is somewhat a victim of its own success after two very strong quarters for Amvuttra, Matteis wrote. Yet, while some investors may have wanted even more from the latest earnings, the underlying fundamentals here still seem strong.To that end, Alnylam said Amvuttras approval last spring for those cardiovascular problems tied to ATTR was a primary reason why patient demand for the drug grew roughly 250% in the fourth quarter. The company estimates that, globally, around 80% of patients with this condition, which stiffens the heart and impairs its function, remain undiagnosed.The number of identified patients has, on average, grown 40% annually since 2019, according to Alnylam.There are simply many tailwinds for the mid-to-long term, even if short-term expectations had gotten ahead of themselves, Matteis wrote.Ascendis numbers overshadowed by competitorDenmark-based Ascendis Pharma also provided an early glance at earnings in January. Its full report, out Wednesday, detailed fourth-quarter product revenue of 240 million euros, or about $279 million. Full-year product revenue hit 684 million euros, with 70% coming from Yorvipath, a drug for a rare illness where the body doesnt produce enough of a hormone that regulates vital minerals.The results were in-line with analyst forecasts. Joseph Schwartz, of Leerink Partners, expects Yorvipaths momentum to continue throughout this year, and described Ascendis goal of the drug surpassing $1 billion in revenue as achievable.The companys share price, however, slumped 5% at markets open Thursday. Though the stock would rebound over the following hours, Ascendis earnings appeared to take a back seat to data from a rival.Early that morning, BridgeBio Pharma disclosed positive findings from a late-stage study evaluating one of its most advanced drugs an oral enzyme-blocker named infigratinib as a growth-inducing treatment for achondroplasia, the most common type of dwarfism. Ascendis has been testing a once-weekly injectable therapy in this setting, and could receive approval from the Food and Drug Administration before the end of February.With few surprises in Ascendis results, the update from BridgeBio served as bigger news and reinforced that this oral option creates competition, wrote Li Watsek of Cantor Fitzgerald.Yaron Werber, a TD Cowen analyst who covers Ascendis, acknowledged that BridgeBios drug appears solid, with clean safety. And, if approved, it will likely dominate the achondroplasia market as both an initial and second-line treatment.In Werbers view, the key to Ascendis being able to compete is securing strong data from a Phase 3 study of its TransCon CNP therapy combined with its already approved product for growth hormone deficiency. In earlier testing, Ascendis said this pairing, when used in certain people with achondroplasia, tripled the effectiveness seen when TransCon CNP was used alone.The combination should eventually become the standard-of-care in achondroplasia, Werber wrote. '

Clinical ResultPhase 3Financial StatementDrug Approval

100 Deals associated with Valbenazine Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Valbenazine Tosylate	N07XX13	DB11915

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Huntington Disease	United States	Neurocrine Biosciences, Inc.	18 Aug 2023
Tardive Dyskinesia	United States	Neurocrine Biosciences, Inc.	11 Apr 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chorea	Phase 3	Argentina	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Belgium	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Brazil	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Israel	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Italy	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Mexico	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Poland	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Portugal	Neurocrine Biosciences, Inc.	15 Apr 2022
Chorea	Phase 3	Spain	Neurocrine Biosciences, Inc.	15 Apr 2022
Hyperkinesis	Phase 3	United States	Neurocrine Biosciences, Inc.	15 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05859698 (KINECT-PRO, CTgov)	Phase 4	Bipolar Disorder \| Schizoaffective disorder \| Depressive Disorder, Major ... View more	59	Valbenazine	jzpwlmfcmp(ilfzdhgcdb) = puxmhoulgf oailopzhvq (stcbzuordf, demdodldru - svjpkctxrl) View more	-	16 Jan 2026
Company_Website Manual	Not Applicable	Huntington Disease \| Tardive Dyskinesia	8	INGREZZA	jkbcwsazza(gjaqrofspa) = sirvnoxzov vgbqkgdywl (aanuodujhr )	Positive	15 Jan 2026
				AUSTEDO XR	jkbcwsazza(gjaqrofspa) = azovaukvol vgbqkgdywl (aanuodujhr )
NCT01688037 (KINECT, PRNewswire) Manual	Phase 3	Cerebral Palsy	-	Valbenazine	fhoeozxhnk(ddqeenlwdy) = did not meet xjmjfjfljv (xtczikxpme ) Not Met View more	Negative	22 Dec 2025
				Placebo
KINECT-HD2 (MDS2025)	Phase 3	Huntington Disease	232	Valbenazine	edtxtdlkav(kvrjcjrpkj) = ygooeesgri wuxhwkxodw (uxgdhpyqgv ) View more	Positive	05 Oct 2025
				Placebo	edtxtdlkav(kvrjcjrpkj) = nagkycglsu wuxhwkxodw (uxgdhpyqgv ) View more
NCT04400331 (KINECT-HD2, MDS2025)	Phase 3	Huntington Disease	154	Valbenazine	lrkjphgdbf(ajilnsvoek) = agkpytvrpo zsztxtwomx (jrfienofwo ) View more	Positive	05 Oct 2025
NCT04102579 (KINECT-HD, PRNewswire) Manual	Phase 3	Huntington Disease	128	INGREZZA	hmexjmxjfx(fhwzxwrsxl) = yvssskbobf vxazghnasw (mqonchhyzn ) View more	Positive	27 Jun 2025
				placebo	hmexjmxjfx(fhwzxwrsxl) = hzifuhwcis vxazghnasw (mqonchhyzn ) View more
NCT03891862 (PRNewswire) Manual	Phase 4	Tardive Dyskinesia	-	INGREZZA	zmooqwguvt(cxpgwhmuca) = 8-week: including mobility (change from baseline: -0.27), self-care (-0.28), usual activities (-0.36) and pain/discomfort (-0.34). 16-week: including significant improvements in mobility (placebo-adjusted difference from Week 8: -0.34) and anxiety/depression (-0.38) compared with those receiving placebo. krdkofxuvo (wnxzismqqk ) View more	Positive	16 May 2025
				Placebo
NCT04400331 (KINECT-HD2, AAN2025)	Phase 3	Huntington Disease Maintenance	154	Valbenazine 40 mg	tnwqvzkukm(iexzjdtkex) = 2.6% wpuxxaldlh (ikeipyroiy ) View more	Positive	07 Apr 2025
				Valbenazine 80 mg
P10-5.019 (AAN2025)	Not Applicable	Tardive Dyskinesia	164	Valbenazine	edazgkzsyx(brtwoonncz) = neeysenqgd nmorfexktc (kzwxtkiidw ) View more	Positive	07 Apr 2025
NCT05859698 (KINECT-PRO, PRNewswire) Manual	Phase 4	Tardive Dyskinesia	59	INGREZZA	orksqtydpd(qwukuskhbv) = Results showed significant and sustained improvements from baseline in all three patient-reported outcome measures, including patients with either mild or moderate/severe TD, with improvements observed as early as four weeks at the lowest dose (40 mg). AIMS scores also showed sustained reductions in involuntary movements, regardless of TD severity or underlying psychiatric condition. fzzljrbpdw (ihggtavvbk ) View more	Positive	27 Feb 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis